Luke Timmerman

T-cell Engagers for Autoimmune Disease: Ken Song on The Long Run - TimmermanReport.com Ken Song is today’s guest on The Long Run. First things first, this episode was recorded before news broke that Candid Therapeutics went public via a reverse merger with RallyBio. But I must say, that...

T-cell engagers for autoimmune disease. Listen to Ken Song, CEO of San Diego-based Candid Therapeutics, on The Long Run podcast. Sponsored by @alphasenseinc.bsky.social & Dash Bio. timmermanreport.com/2026/03/t-ce...

Science and Industry Need to Push Back Hard. Guest editorial by @cdelawalla.bsky.social @standupforscience.bsky.social timmermanreport.com/2026/01/scie...

Next Stop: Kilimanjaro 2026 for Damon Runyon Cancer Research - TimmermanReport.com The biotech industry can do amazing things when concentrated on an audacious goal. Like curing cancer. I’m fired up to announce the next Timmerman Traverse for Damon Runyon Cancer Research Foundation....

Next stop: Kilimanjaro 2026 for Damon Runyon Cancer Research Foundation Meet the team of biotech leaders raising $1 million for cancer research and hiking up the highest peak in Africa. timmermanreport.com/2025/09/next...

Why is Vineeta Agarwala joining the Timmerman Traverse for a 3rd time on Oct. 4? Watch.

Timmerman Traverse for Life Science Cares Raises Another $1.1M to Fight Poverty in 2025 - TimmermanReport.com Another Timmerman Traverse for Life Science Cares is in the books. This year, we raised $1.15 million from more than 1,000 donors to fight poverty in biotech hubs around the US. We raised awareness of...

Timmerman Traverse for Life Science Cares raises another $1.1M to fight poverty. timmermanreport.com/2025/08/timm...

CAR-T Cells Against Solid Tumors: Sabah Oney on The Long Run - TimmermanReport.com Sabah Oney is today’s guest on The Long Run. Sabah is the CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics. This startup is developing engineered CAR-T cell therapies for solid tum...

CAR-T cells against solid tumors. Listen to Sabah Oney, CEO of Dispatch Biotherapeutics, on The Long Run. timmermanreport.com/2025/08/car-...

VIDEO: Phil Sharp and Bill Haney on 'Cracking the Code' - TimmermanReport.com Science and society have always had an uneasy relationship. Yet there are always people out there seeking to build bridges of understanding.  I recently moderated a conversation at MIT with Phil Sharp...

VIDEO: Conversation with Phil Sharp and Bill Haney about 'Cracking the Code.' Documentary film about an inspiring life in science. timmermanreport.com/2025/08/vide...

Creative Ways to Back Young Scientists: Andy Rachleff and Yung Lie on The Long Run - TimmermanReport.com Yung Lie and Andy Rachleff are today’s guests on The Long Run. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation, based in New York. Andy is the board chair. Andy was one of...

Creative Ways to Back Young Scientists. Listen to Yung Lie and Andy Rachleff of Damon Runyon Cancer Research Foundation on The Long Run podcast. timmermanreport.com/2025/07/crea...

YouTube video by Damon Runyon Cancer Research Foundation Thank you to the sponsors of the 2025 Timmerman Traverse to Everest Base Camp!

Sublime scenery. Smiling faces. Thanks to the sponsors of the Timmerman Traverse for Damon Runyon Cancer Research Foundation. Watch this for 90 seconds of joy. www.youtube.com/watch?v=LwzE...

Finding Therapies in Long Non-Coding RNA: John Rinn on The Long Run - TimmermanReport.com John Rinn is today’s guest on The Long Run. John is the Leslie Orgel and Marvin Caruthers professor of RNA science at the University of Colorado in Boulder. His research is focused on long non-coding ...

Finding Therapies in Long Non-Coding RNA. John Rinn of University of Colorado and Lincswitch Therapeutics is the latest guest on The Long Run. Available on Apple Podcasts, Spotify, and YouTube. timmermanreport.com/2025/06/find...

BIO International Convention | Storytelling Stage Experience powerful stories from researchers, patients, and innovators at the BIO 2025 Storytelling Stage, June 16–19 in Boston.

Join me at 3 pm Mon. June 16 at the BIO International Convention's Storytelling Stage to hear about the past, present, and future of Timmerman Traverse for @lifesciencecares.bsky.social @damonrunyon.org convention.bio.org/program/bio-...

Request an Invitation to the Timmerman Traverse - TimmermanReport.com Timmerman Traverse is looking for a few good men and women. Opportunities are here for people who are physically fit, enjoy nature, thrive in community, and who want to roll up the sleeves for worthy ...

Request an Invitation to the Timmerman Traverse. timmermanreport.com/2025/06/requ...

A New and Old Idea for Cardiovascular Disease & Diabetes: Ethan Weiss & Josh Lehrer on The Long Run - TimmermanReport.com Ethan Weiss and Josh Lehrer are today’s guests on The Long Run. Ethan is the co-founder and chief scientific officer of South San Francisco-based Marea Biosciences. Josh is the CEO. They are seeking t...

A New (and Old) Idea for Cardiovascular Disease & Diabetes. @ethanjweiss.bsky.social and Josh Lehrer of Marea Therapeutics are the latest guests on The Long Run. timmermanreport.com/2025/05/a-ne...

Reclaiming Biotech's Edge: In Defense of Taking Disciplined Risk. Guest editorial by Anika Gupta Vatsa. timmermanreport.com/2025/05/recl...

Timmerman Traverse for @lifesciencecares.bsky.social is at $535,178 in pending and closed donations. Halfway to the $1M team goal with three months to go. Thanks to major sponsors Fenwick & West, KCap Biotechnology Fund and HSBC Innovation Banking. Looking forward to our PNW adventure!

Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run - TimmermanReport.com Peyton Greenside is today’s guest on The Long Run. Peyton is the co-founder and CEO of San Mateo, Calif.-based BigHat Biosciences. The company was started in 2019 to build on advances in synthetic bio...

Biologic Drug Discovery Made Faster. Peyton Greenside of BigHat Biosciences is the latest guest on The Long Run podcast. timmermanreport.com/2025/05/biol...

A Sublime Experience: Views of Timmerman Traverse for Damon Runyon Cancer Research - TimmermanReport.com Kathmandu, Nepal We did it together. The Timmerman Traverse for Damon Runyon Cancer Research Foundation completed a splendid expedition to Everest Base Camp on Apr. 23, 2025. This trip succeeded on ev...

A Sublime Experience. See the photo highlights of Timmerman Traverse for Damon Runyon Cancer Research Foundation. timmermanreport.com/2025/05/a-su...

Honored.

We all made it! The Timmerman Traverse for Damon Runyon Cancer Research Foundation team arrived at Everest Base Camp (elev. 17,600 feet) on Apr. 23, 2025. Another awe-inspiring day in the mountains, supporting brave and bold cancer research. Thanks to all who supported this marvelous experience.

Views from Day 7 of Timmerman Traverse for Damon Runyon Cancer Research Foundation.

Stunning views from Timmerman Traverse for Damon Runyon Cancer Research Foundation. Day 5. We’re at Dingboche, elevation 14,300 ft. The Himalayas in full glory.

What US Biotech Can Do to Meet the Moment. By David Li, CEO of SF-based Meliora Therapeutics. timmermanreport.com/2025/04/a-ne...

Nobel laureate: I owe America my success. Today, its scientific future is in danger | CNN Dr. Ardem Patapoutian says he watches “with deep sadness as the United States’ remarkable scientific enterprise, which took generations of hard work and national investment to build, faces a concerted...

Great article by @nobelprize.bsky.social laureate @ardemp.bskyverified.social outlining the health, economic and national security benefits of US biomedical research, and the devastation of government efforts to destroy our leading edge.

www.cnn.com/2025/04/09/h...

We Need an mRNA Champion in a Red Cape - TimmermanReport.com I grew up in an era of Superman comic books. Superman captivated the imagination of a generation of kids like me. It told stories of an otherwise ordinary human who could achieve extraordinary feats o...

Dr. Larry Corey was a fan of the Superman comics as a kid. Now he's looking for a hero in a red cape to stand up for mRNA vaccines and therapies. timmermanreport.com/2025/04/we-n...

A favorite sign from the Saturday rally in Seattle.

Meet the Timmerman Traverse for Life Science Cares 2025 Team - TimmermanReport.com The 5th annual Timmerman Traverse for Life Science Cares is fired up and ready for outdoor adventure in 2025. We’re on a mission to raise $1 million to fight poverty.  This year’s team is preparing fo...

Meet the 2025 Timmerman Traverse for Life Science Cares 2025 team. Men and women on a mission to raise $1 million to fight poverty in BOS, SF, SD, PHI and NYC. Top sponsor: Fenwick & West. CC @robperez.bsky.social timmermanreport.com/2025/04/meet...

Timmerman Traverse for Damon Runyon Hits $700K Goal, Fueling Cancer Research - TimmermanReport.com Times are tough in biotech, but this is an industry where we learn, adapt, and move forward. I’m proud to announce that the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit ...

Goal: the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit the fundraising goal of $700,000 for high-risk / high-reward cancer research. Team gearing up for trek to Everest Base Camp. timmermanreport.com/2025/04/timm...

Longevity Is Having A Moment - TimmermanReport.com Dying, with few exceptions, has never been especially popular, and our shared interest in not dying hardly constitutes breaking news.  Nevertheless, the aspiration of living longer — and remaining hea...

Longevity is Having a Moment, and the Secret Weapon of GLP1 Weight Loss Medicines. Two smart new pieces by @dshaywitz.bsky.social timmermanreport.com/2025/03/long... timmermanreport.com/2025/03/glp-...

A Moment of Peril and Promise - TimmermanReport.com Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, a...

A Moment of Peril and Promise. (Sub. Req.) timmermanreport.com/2025/03/sole...

The State of Possible Conference - MassBio Join industry leaders at the State of Possible Conference 2025 on March 26, hosted by MassBio in Boston. Discover insights on the future of biotech, pharma, and innovation in the Massachusetts life sc...

I'll be in Boston tomorrow to interview George Church, Abbie Celniker, and Bruce Booth at the MassBio State of Possible conference. @massbio.bsky.social. www.massbio.org/state-of-pos...